Compass Therapeutics, Inc. (CMPX)
1.12
-0.02
(-1.32%)
USD |
NASDAQ |
Sep 25, 16:00
1.14
+0.02
(+1.79%)
After-Hours: 19:59
Compass Therapeutics Research and Development Expense (Annual) : 55.69M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 55.69M |
| December 31, 2024 | 41.75M |
| December 31, 2023 | 37.42M |
| December 31, 2022 | 29.22M |
| Date | Value |
|---|---|
| December 31, 2021 | 19.77M |
| December 31, 2020 | 14.90M |
| December 31, 2019 | 22.45M |
| December 31, 2018 | 27.10M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Capricor Therapeutics, Inc. | 83.50M |
| Ardelyx, Inc. | 68.47M |
| ARS Pharmaceuticals, Inc. | 13.18M |
| Upstream Bio, Inc. | 136.81M |
| Sionna Therapeutics, Inc. | 60.26M |